{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T21:38:50Z","timestamp":1759959530496},"reference-count":11,"publisher":"Japan Atherosclerosis Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2024,1,1]]},"DOI":"10.5551\/jat.ed245","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:27:28Z","timestamp":1697495248000},"page":"21-22","source":"Crossref","is-referenced-by-count":3,"title":["Residual Cardiovascular Risk Determined through Posthoc Analysis of the REAL-CAD Trial"],"prefix":"10.5551","volume":"31","author":[{"given":"Yasuhiro","family":"Endo","sequence":"first","affiliation":[{"name":"Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College"},{"name":"Division of Environmental Medicine, National Defense Medical College Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Ikewaki","sequence":"additional","affiliation":[{"name":"Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE: Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease. Diabetes, 2020; 69: 508-516","DOI":"10.2337\/dbi19-0007"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S: Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation, 2014; 129: 635-642","DOI":"10.1161\/CIRCULATIONAHA.113.004406"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, Ballantyne CM: Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol, 2014; 34: 1069-1077","DOI":"10.1161\/ATVBAHA.114.303284"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ: HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, 2010; 376: 333-339","DOI":"10.1016\/S0140-6736(10)60713-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017; 377: 1119-1131","DOI":"10.1056\/NEJMoa1707914"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kamiya K, Takei M, Nagai T, Miyoshi T, Ito H, Fukumoto Y, Obara H, Kakuma T, Sakuma I, Daida H, Iimuro S, Shimokawa H, Kimura T, Nagai R, Anzai T: Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study. J Atheroscler Thromb, 2024; 31: 61-80","DOI":"10.5551\/jat.64304"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hirata A, Okamura T, Hirata T, Sugiyama D, Ohkubo T, Okuda N, Kita Y, Hayakawa T, Kadota A, Kondo K, Miura K, Okayama A, Ueshima H: Relationship Between Non-fasting Triglycerides and Cardiovascular Disease Mortality in a 20-year Follow-up Study of a Japanese General Population: NIPPON DATA90. J Epidemiol, 2022; 32: 303-313","DOI":"10.2188\/jea.JE20200399"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni G, Jones S, Pompili G, Psaltis PJ: Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging, 2022; 15: 1308-1321","DOI":"10.1016\/j.jcmg.2022.03.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Ridker PM, Tuttle KR, Perkovic V, Libby P, MacFadyen JG: Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J, 2022; 43: 4832-4844","DOI":"10.1093\/eurheartj\/ehac444"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/1\/31_ED245\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:56:54Z","timestamp":1715576214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/1\/31_ED245\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.ed245","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"ED245"}}